

|                    |  |
|--------------------|--|
| 1. Record Nr.      | UNINA9910808713803321  |
| Autore             | Kazmierski Wieslaw M   |
| Titolo             | Antiviral Drugs : From Basic Discovery Through Clinical Trials   |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011   |
| ISBN               | 1-283-20363-4<br>9786613203632<br>0-470-92935-9<br>0-470-92934-0   |
| Edizione           | [1st ed.]  |
| Descrizione fisica | 1 online resource (470 p.)   |
| Disciplina         | 615/.7924  |
| Soggetti           | Antiviral Agents -- therapeutic use<br>Antiviral agents<br>Clinical Trials as Topic<br>Drug Discovery<br>Drug Evaluation<br>Epidemiologic Studies<br>Chemistry, Pharmaceutical<br>Evaluation Studies as Topic<br>Investigative Techniques<br>Anti-Infective Agents<br>Epidemiologic Methods<br>Pharmacology<br>Therapeutic Uses<br>Health Care Evaluation Mechanisms<br>Chemistry<br>Biological Science Disciplines<br>Natural Science Disciplines<br>Quality of Health Care<br>Public Health<br>Pharmacologic Actions<br>Environment and Public Health<br>Health Care Quality, Access, and Evaluation<br>Chemical Actions and Uses<br>Delivery of Health Care<br>Antiviral Agents<br>Health & Biological Sciences<br>Pharmacy, Therapeutics, & Pharmacology |

|                         |  |
|-------------------------|--|
| Lingua di pubblicazione | Inglese  |
| Formato                 | Materiale a stampa   |
| Livello bibliografico   | Monografia   |
| Note generali           | Description based upon print version of record.  |
| Nota di contenuto       | <p>ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients</p> <p>7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir</p> <p>14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection</p> <p>21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir</p> <p>29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate</p> |
| Sommario/riassunto      | This book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense so   |